| 產(chǎn)品編號(hào) | bs-5541R-PE-Cy7 |
| 英文名稱 | Rabbit Anti-phospho-PTK2 (Tyr576+Tyr577)/PE-Cy7 Conjugated antibody |
| 中文名稱 | PE-Cy7標(biāo)記的磷酸化粘著斑激酶抗體 |
| 別 名 | PTK2 (phospho Y576/Y577); FAK (phospho Y576 + Y577); FADK 1; FADK; FAK related non kinase polypeptide; FAK1; FAK1_HUMAN; Focal adhesion kinase 1; Focal adhesion Kinase; Focal adhesion kinase isoform FAK Del33; Focal adhesion kinase related nonkinase; FRNK; p125FAK; pp125FAK; PPP1R71; Protein phosphatase 1 regulatory subunit 71; Protein tyrosine kinase 2; Protein-tyrosine kinase 2; Ptk2; PTK2 protein tyrosine kinase 2. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 116kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human PTK2 around the phosphorylation site of Tyr576+Tyr577 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Plays a potential role in oncogenic transformations resulting in increased kinase activity. [SUBCELLULAR LOCATION] Cell junction, focal adhesion. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=Constituent of focal adhesions. Subcellular Location: Cell junction, focal adhesion. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cell cortex. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, centrosome. Nucleus. Tissue Specificity: Detected in B and T-lymphocytes. Isoform 1 and isoform 6 are detected in lung fibroblasts (at protein level). Ubiquitous. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. FAK subfamily. Contains 1 FERM domain. Contains 1 protein kinase domain. Database links: Entrez Gene: 5747 Human Entrez Gene: 14083 Mouse Omim: 600758 Human SwissProt: Q05397 Human SwissProt: P34152 Mouse Unigene: 395482 Human Unigene: 254494 Mouse Unigene: 2809 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. ????FAK是整合蛋白介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)中的重要成員,有酪氨酸蛋白激酶活性,并可自身磷酸化,FAK本身是胱冬肽酶(caspase)的底物。作為信號(hào)分子的FAK參與抑制細(xì)胞凋亡并直接參與細(xì)胞多種功能的調(diào)節(jié)。 ????1.FAK 局部粘著斑激酶，是一種酪氨酸激酶;腫瘤細(xì)胞的侵襲性生長(zhǎng)是一個(gè)多步驟的復(fù)雜過(guò)程，有多種生物化學(xué)因子參與其中,局部粘著斑激酶（focal adhesion kinase, FAK）介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)系統(tǒng)就是其中最為重要的細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)途徑之一。腫瘤細(xì)胞必須黏附于細(xì)胞外基質(zhì)，通過(guò)促進(jìn)依賴于PTK激酶活性的細(xì)胞外基質(zhì)信號(hào)轉(zhuǎn)導(dǎo)，進(jìn)而影響細(xì)胞的黏附、運(yùn)動(dòng)與遷移。 ????2.粘著斑激酶(focal adhesion kinase,FAK)是整合蛋白介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)中的重要成員,有酪氨酸蛋白激酶活性,并可自身磷酸化；為信號(hào)分子的FAK,還與細(xì)胞內(nèi)其他信號(hào)轉(zhuǎn)導(dǎo)通路存在串話(crosstalk),直接參與了細(xì)胞多種功能的調(diào)節(jié)。 ????3.盡管FAK的確切功能尚不清楚,但若干實(shí)驗(yàn)均提示FAK可能有兩個(gè)作用,一是在細(xì)胞鋪展和移動(dòng)時(shí),FAK參與粘著斑形成和調(diào)節(jié)；二是FAK參與信號(hào)轉(zhuǎn)導(dǎo)過(guò)程,以告知細(xì)胞核其細(xì)胞已錨定了。近年有關(guān)FAK在細(xì)胞凋亡中的作用也業(yè)已肯定。 |
